Imatinib (STI571)

目录号:S2475 别名: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571)是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。

规格 价格 库存 购买数量  
RMB 571.38 现货
RMB 980.11 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献35篇:

客户使用该产品的6个实验数据:

  • Ba/F3-p210T315I cells were treated with indicated concentrations of imatinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck.

    Targeting KITLG through c-KIT inhibition using Imatinib; one representative experiment is shown (n = 4).

    Oncotarget, 2016, 7(34):54583-54595. Imatinib (STI571) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with imatinib. K562 cells (a and c) and MEG-01 cells (b and d) were incubated at 37 ◦C for 15 min with imatinib transport buffer, and then incubated with 0.5 Ci of [3H] thymidine or [3H] cytarabine for an additional 5 min in presence of imatinib. Cells were then washed 3 times, lysed and radioactivity associated to cell pellets was quantified. DMSO, dimethylsulfoxide; DPD, dipyridamole.

    Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck.

    ZFX regulates imatinib sensitivity and PI3K/Akt signaling pathway in CML cells. Viability of cells transfected with si-ZFX at the indicated doses of imatinib for 24 h (a). Colonies of leukemia cells and imatinib-resistant cells transfected with si-ZFX following treatment with imatinib for 10 days (b). Western blot analysis of Akt, p-Akt, CyclinD1, CyclinE1, Bcl-2, and Caspase-3 in K562 and K562/G01 cells transfected with si-ZFX for 2 days (c). The relative densities of proteins were quantified and normalized to b-Actin (d). Values represented the mean ± SD data from experiments in triplicate. *P\0.05 and **P\0.01

    Cell Biochem Biophys, 2016, 74(2):277-83. Imatinib (STI571) purchased from Selleck.

  • Cell Viability assay results. A2C12, BetaD5, GammaA3, GammaD12, A549, CaCo2, HepG2 cell lines were treated with imatinib mesylate for 24h and 96h.

    Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck.

    A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ±sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.

    Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck.

产品安全说明书

PDGFR抑制剂选择性比较

生物活性

产品描述 Imatinib (STI571)是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。
特性 Imatinib 是多靶点酪氨酸激酶抑制剂。
靶点
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
体外研究

体外抑制一组酪氨酸和丝/苏氨酸蛋白激酶实验,说明Imatinib有效抑制v-Abl 酪氨酸激酶和PDGFR,IC50 分别为 0.6 和 0.1 μM。[1]Imatinib抑制 野生型 c-kit激酶活性的SLF依赖性激活,IC50约为0.1 μM, 与抑制PDGFR所需的浓度相似。[2] Imatinib 抑制人类支气管类癌细胞NCI-H727和胰腺类癌细胞 BON-1生长,IC50分别为 32.4 和 32.8 μM。[3] 最新研究显示Imatinib作用于慢性粒细胞白血病,通过下调hERG1 K(+)通道,具有恢复其抗白血病效果的潜力,而hERG1 K(+) 通道在白血病细胞中高表达,且易引发白血病。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 NFP4SZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0TWM2OD1yLkC3N|A1KM7:TR?= M4XIfXNCVkeHUh?=
EM-2 NWnXcpJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vyUWlEPTB;MD6wPFg5KM7:TR?= MYPTRW5ITVJ?
MEG-01 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonsTWM2OD1yLkC4PVIyKM7:TR?= MlrVV2FPT0WU
BV-173 NWDRRYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn6[I1KSzVyPUCuNVg4PCEQvF2= MXzTRW5ITVJ?
K-562 NF3TVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jtOmlEPTB;MD6yNlQ{OiEQvF2= NYLrZ|E{W0GQR1XS
CGTH-W-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX6bW9HUUN3ME2wMlM5Ozd2IN88US=> MYfTRW5ITVJ?
ST486 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNki1OEDPxE1? NEjBO5BUSU6JRWK=
NCI-H1436 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPBfVdVUUN3ME2wMlk4QDBzIN88US=> M1jDeXNCVkeHUh?=
NOS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHTUHZ1UUN3ME2xMlY2Ozh|IN88US=> NV7mdWM3W0GQR1XS
A498 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfqWXp7UUN3ME2yMlU4OjJ|IN88US=> MoPhV2FPT0WU
BE-13 NXjpWYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwNkKxNFYh|ryP M1e0PXNCVkeHUh?=
SUP-T1 M4Dw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwOEK5NFch|ryP NWL5V3RnW0GQR1XS
NCI-H1770 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDxTWM2OD13LkW3NlYzKM7:TR?= MnfLV2FPT0WU
IMR-5 M4XScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jNOmlEPTB;Nj6yNlE1PyEQvF2= MWPTRW5ITVJ?
LB2241-RCC NVz4bFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwMEezPFQh|ryP MoXnV2FPT0WU
TGBC24TKB NIPFUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTN5NvUUN3ME24MlM1ODV{IN88US=> M3e1W3NCVkeHUh?=
SCC-15 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PsR2lEPTB;MUCuO|c5QCEQvF2= M4Doc3NCVkeHUh?=
BB49-HNC NHHNcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfpTWM2OD1zND6zN|M2KM7:TR?= NFqwUG5USU6JRWK=
ES7 NF7hboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInpPGVKSzVyPUG0Mlc{PzlizszN Ml3uV2FPT0WU
LB2518-MEL NHyxUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF4Lk[wPVQh|ryP NF3EZVFUSU6JRWK=
NCI-H510A NVnUR5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5LkK0OFIh|ryP NFW1NJlUSU6JRWK=
TE-441-T MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDnd4FKSzVyPUG3MlI5QDZizszN M3v3RnNCVkeHUh?=
HH NV3nT3BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\L[pVTUUN3ME2xO{4{QTl7IN88US=> NWXUSJBYW0GQR1XS
LC4-1 M{nMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELMUY5KSzVyPUG4MlA3PTJizszN Mm\ZV2FPT0WU
KARPAS-45 M4ex[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTWTWpOUUN3ME2xPE4yQDR6IN88US=> NITqdpZUSU6JRWK=
LB1047-RCC MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qdnBKSzVyPUG4MlQ1PTJizszN MYrTRW5ITVJ?
NKM-1 NIX2c5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LhZWlEPTB;MUmuN|U2OiEQvF2= NHe5RYNUSU6JRWK=
SCLC-21H M{TIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf0PVVyUUN3ME2yNE4yOjR4IN88US=> MkP4V2FPT0WU
RS4-11 NIrUOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX3TWM2OD1{MD6zN|A5KM7:TR?= M4T0UnNCVkeHUh?=
ALL-PO M1yycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jPRmlEPTB;MkCuPFE1QSEQvF2= M13zUnNCVkeHUh?=
GDM-1 NW\2UVM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW5UJlKSzVyPUKyMlU6PDVizszN NVrqbG9yW0GQR1XS
DMS-79 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DrV2lEPTB;MkSuOFk{PCEQvF2= MXXTRW5ITVJ?
MPP-89 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkewTWM2OD1{NT62PFc1KM7:TR?= NIH3V3FUSU6JRWK=
NB10 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfi[mRKSzVyPUK2MlQ3QTlizszN M3P0R3NCVkeHUh?=
LS-513 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq3Z|FvUUN3ME2yOk45QDR5IN88US=> MljQV2FPT0WU
L-540 NEPXfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJ4LkmxOFMh|ryP MYTTRW5ITVJ?
ES1 NIP3W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0VWtwUUN3ME2yO{42OjFizszN NFTIN21USU6JRWK=
NTERA-S-cl-D1 NYjRUnl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnqTWM2OD1|MD61NFk{KM7:TR?= MkSwV2FPT0WU
EW-1 NIq4NJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPsTWM2OD1|Mj65OFU1KM7:TR?= MkfXV2FPT0WU
Calu-6 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjiXGJGUUN3ME2zN{4yQDV3IN88US=> MVLTRW5ITVJ?
CTV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfac5Q3UUN3ME2zN{46Pzh7IN88US=> M3LNfXNCVkeHUh?=
YT NWq0e5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN6LkWyNFkh|ryP NXm1[nRsW0GQR1XS
TE-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4O2lEPTB;NEGuNlc6QCEQvF2= MVLTRW5ITVJ?
HT-144 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fuSWlEPTB;NEGuOVQ5PiEQvF2= MnjmV2FPT0WU
EW-13 NV72eY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm4TII4UUN3ME20Nk4zPzlzIN88US=> MVfTRW5ITVJ?
KALS-1 M1u5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEXGtKSzVyPUSzMlE{OjlizszN MlH1V2FPT0WU
MOLT-16 M3\FTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTlSIpKSzVyPUS1MlA4PTJizszN NGTrZlBUSU6JRWK=
D-336MG Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR3Lkm1PVkh|ryP M{TEdXNCVkeHUh?=
TE-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULTPWxHUUN3ME20Ok43PTNizszN NUT6SHFCW0GQR1XS
EB2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELxSFdKSzVyPUS2MlY6QSEQvF2= NVTUNoRtW0GQR1XS
SK-N-DZ MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXvOmNCUUN3ME20PE4xQTZzIN88US=> MWjTRW5ITVJ?
SW684 NGPxc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR6LkK2PVUh|ryP NV;pWGVXW0GQR1XS
EW-18 NFTNTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pelNKSzVyPUS4MlQ{QTVizszN NULrT2ZqW0GQR1XS
RL95-2 NXfzeYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu3UZhKSzVyPUWwMlA4OSEQvF2= MVvTRW5ITVJ?
CHP-126 NVTnR2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiTGlEPTB;NUCuPFkxPSEQvF2= Mnr5V2FPT0WU
NCI-H1395 NXHjPGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r3dmlEPTB;NUGuO|g{PSEQvF2= MoGxV2FPT0WU
TE-15 NGK1RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2V2lEPTB;NUKuNlU2PiEQvF2= NVXoXIlGW0GQR1XS
ES4 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DzS2lEPTB;NUKuPVc4PSEQvF2= MULTRW5ITVJ?
TE-1 NGrkeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH4ToVrUUN3ME21N{46PDV3IN88US=> NUjDR491W0GQR1XS
SIMA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTV5LkOzNVEh|ryP M2LONXNCVkeHUh?=
LB647-SCLC M4XxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZ2LkGxPFgh|ryP NVGwSWxCW0GQR1XS
KY821 MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2OD14ND6yOVUzKM7:TR?= NGDQemJUSU6JRWK=
LC-2-ad NYmzWoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLXTWM2OD14NT63OlAyKM7:TR?= NFfkeXZUSU6JRWK=
KP-N-RT-BM-1 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW5cpVKSzVyPU[2MlY{PjZizszN MXfTRW5ITVJ?
SW872 NH7EbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXRPJZKSzVyPU[3MlQ{QDJizszN NYTZcZFUW0GQR1XS
ES5 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnId4ZMUUN3ME22O{43QTZ6IN88US=> M4PU[XNCVkeHUh?=
SK-NEP-1 M4TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZ6LkO4NFMh|ryP NUXpN291W0GQR1XS
RPMI-6666 NF:yeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTdzLkCzNkDPxE1? M3PNTnNCVkeHUh?=
UACC-812 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rofmlEPTB;N{GuNVYxQSEQvF2= M1LQPXNCVkeHUh?=
COLO-829 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD15Mj62PVg4KM7:TR?= MnzSV2FPT0WU
KP-N-YS M{PYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HmS2lEPTB;N{KuO|E{QSEQvF2= NX7LS5duW0GQR1XS
GI-1 NELN[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLlO4RFUUN3ME23N{4zQDZ6IN88US=> Mn\TV2FPT0WU
ETK-1 NYLUNHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDEUWxKSzVyPUezMlQ6OzJizszN M3fiWnNCVkeHUh?=
LXF-289 NVfVPHM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKyPXR4UUN3ME23N{44OjlizszN NY\GfG5oW0GQR1XS
CAS-1 NFfYV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XSS2lEPTB;N{OuPFg2PyEQvF2= MmXNV2FPT0WU
EW-22 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTd2LkexNVUh|ryP M{faRnNCVkeHUh?=
NCI-H2196 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0[JdQUUN3ME23OU43Ozd7IN88US=> NUDwSpQ2W0GQR1XS
EoL-1-cell NG\IRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\3R2lEPTB;OEGuOlk3OyEQvF2= MYDTRW5ITVJ?
D-247MG NULFNVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W0Z2lEPTB;OEKuNFI1QCEQvF2= NYezdo9JW0GQR1XS
Becker NF7BU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkeyTWM2OD16Mj6zOFgyKM7:TR?= MmjRV2FPT0WU
IST-MEL1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTh{LkO0PFIh|ryP M1HBenNCVkeHUh?=
MDA-MB-134-VI NUG1cYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3XTpVKSzVyPUiyMlU6QTZizszN NFXSO5ZUSU6JRWK=
NCI-H1092 NFnzfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnDTWM2OD16ND6wNVk4KM7:TR?= NF7OenNUSU6JRWK=
KINGS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH76Z3JKSzVyPUi2MlE3OThizszN MnzSV2FPT0WU
HCC2218 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnTTWM2OD16Nj63PVE{KM7:TR?= MWLTRW5ITVJ?
GI-ME-N NH\3dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH6PXVnUUN3ME24O{44Pjl7IN88US=> M3H1XnNCVkeHUh?=
AM-38 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTh6LkO5OVMh|ryP MkLWV2FPT0WU
KNS-42 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PCSGlEPTB;OEmuNVAyQCEQvF2= NFHVVXpUSU6JRWK=
C8166 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT5TWM2OD16OT62NVI2KM7:TR?= NU[4OGM3W0GQR1XS
Ramos-2G6-4C10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[3flJKSzVyPUi5Mlg4OTlizszN NXrSTHFjW0GQR1XS
CTB-1 NXW3OmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3znb2lEPTB;OUCuOlM2PyEQvF2= MXnTRW5ITVJ?
HCE-4 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHWS5hKSzVyPUmxMlE{OzZizszN NHTKXXZUSU6JRWK=
NCI-H526 M3vNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnKTWM2OD17Mj60NVA{KM7:TR?= MVXTRW5ITVJ?
ECC4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTlTWM2OD17ND6yOVU2KM7:TR?= M{TlPXNCVkeHUh?=
NCCIT MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq3epE4UUN3ME25OU4{Ojl{IN88US=> NI[xRlFUSU6JRWK=
MZ7-mel MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLrWnhTUUN3ME25OU46ODRizszN MmrWV2FPT0WU
COLO-684 M2rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTl4LkKzPFUh|ryP MnzSV2FPT0WU
SU-DHL-1 NYG3emI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvqXZgzUUN3ME25Ok46QDR{IN88US=> MlXGV2FPT0WU
SF126 NXizUoJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTl5LkWyNVch|ryP NXn5PGRIW0GQR1XS
NMC-G1 M4nLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTFfoRKSzVyPUm4MlQ2PTRizszN MYHTRW5ITVJ?
NB14 NFjKTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTtbGl{UUN3ME25PE46OjB6IN88US=> NVXlelg2W0GQR1XS
VA-ES-BJ M4X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGwbmtKSzVyPUm5MlQxPTZizszN MYfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Imatinib作用于三种从新鲜人类小细胞肺癌衍生的移植瘤,具有不同的抗肿瘤效果,抑制SCLC6, SCLC61和 SCLC108 肿瘤生长分别达80%, 40% 和78%,而对SCLC74 生长没有明显抑制效果。[5] Imatinib 处理高脂肪饲喂的ApoE(-/-)小鼠, 显著降低高脂肪诱导的脂质染色区,按10,20和 40 mg/kg剂量饲喂,与未经高脂肪饮食处理的对照组相比,脂质染色区分别降低 30%, 27% 和 35%,且抑制颈动脉脂质堆积。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

PDGF 受体激酶活性 :

从BALB/c 3T3 细胞抽提物中使用兔抗血清免疫沉淀PDGF受体,然后小鼠PDGF受体置于冰上2小时。使用蛋白A-琼脂糖磁珠,用于收集抗原-抗体复合体。使用TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100)冲洗免疫沉淀反应两次,,使用TNE (50 mM Tris, pH 7.5, 140 mM EDTA)冲洗一次,再使用激酶 buffer (20 mM Tris, pH 7.5,10 mM MgCl2)冲洗一次。在 4oC下使用PDGF(50 ng/mL)刺激10分钟,在反应混合物中加入不同浓度Imatinib。与10 μCi [7-33P]-ATP及l μM ATP 在4oC下温育10分钟,然后测定PDGF受体激酶活性。通过 SDS-PAGE 在7.5% 凝胶上分离免疫复合物。
细胞实验:

[3]

+ 展开
  • Cell lines: BON-1 和 NCI-H727 细胞
  • Concentrations: 0 到 100 μM
  • Incubation Time: 48 小时
  • Method:

    BON-1 细胞和 NCI-H727 细胞按一式三份接种在平底96孔板上,分别在补充10%胎牛血清的 DMEM 或 RPMI 1640 完全培养基中粘附过夜,更换培养基为无血清培养基(阴性对照) 或含连续稀释Imatinib的无血清培养基。48小时后 (对照组细胞不汇合),通过MTT实验测定代谢活性细胞数,使用Packard Spectra 酶标仪在540 nm处测定吸光值。按如下公式计算抑制生长率: 抑制率=(1 − a / b) × 100%, a 和 b 分别为实验组和对照组的吸光值。


    (Only for Reference)
动物实验:

[5]

+ 展开
  • Animal Models: SCLC6, SCLC61, SCLC 74 和SCLC108小细胞注射进 Swiss小鼠 (nu/nu,雌性)
  • Formulation: Imatinib 在水中稀释
  • Dosages: 70 或 100 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 493.6
化学式

C29H31N7O

CAS号 152459-95-5
稳定性 powder
in solvent
别名 CGP057148B, ST-1571

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03343600 Recruiting Patients Who Have Received Allo-HSCT National Taiwan University Hospital|Far Eastern Memorial Hospital|Tri-Service General Hospital|National Cheng-Kung University Hospital|Hualien Tzu Chi General Hospital November 9 2017 Phase 2
NCT01343173 Completed Chronic Myeloid Leukaemia University Hospital Bordeaux April 6 2011 Not Applicable
NCT02812693 Withdrawn Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma Joanne Jeter|National Cancer Institute (NCI)|Merck Ltd.|Ohio State University Comprehensive Cancer Center November 4 2016 Phase 1|Phase 2
NCT02461849 Recruiting Advanced Refractory Cancer Samsung Medical Center April 4 2014 Phase 2
NCT02644525 Not yet recruiting Loaisis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) December 31 2015 Phase 2
NCT00471497 Active not recruiting Myelogenous Leukemia Chronic Novartis Pharmaceuticals|Novartis July 31 2007 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • 回答:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • 问题 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • 回答:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

相关PDGFR产品

Tags: 购买Imatinib (STI571) | Imatinib (STI571)供应商 | 采购Imatinib (STI571) | Imatinib (STI571)价格 | Imatinib (STI571)生产 | 订购Imatinib (STI571) | Imatinib (STI571)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID